PLANO, Texas, July 30, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced the appointment of Martin W. Edwards, M.D. to its Board of Directors, effective August 3, 2020.
Since 2003, Dr. Edwards has held various positions at Novo Holdings, a life sciences investment firm, and most recently, he has served as a part-time Senior Partner. Earlier in his career, he was Corporate VP and Global Head of Drug Development for Novo Nordisk, where he led all aspects of pre-clinical and clinical drug development. Dr. Edwards currently serves on the board of directors of three publicly traded pharmaceutical companies, Inozyme Pharma, Inc., Kalvista Pharmaceuticals, Inc., and Verona Pharma plc. He previously served on the board of directors of CoLucid Pharmaceuticals, Inc., which was a publicly traded pharmaceutical company. Dr. Edwards trained in physiology and medicine at the University of Manchester, where he obtained his M.D. He is a Member of the Royal College of Physicians, a Member with distinction of the Royal College of General Practitioners, a Fellow of the Faculty of Pharmaceutical Medicine, and holds an M.B.A. from the University of Warwick.
“I’m honored to join Reata’s Board, and I look forward to the opportunity to help oversee the Company’s important work,” said Dr. Edwards. “I’m excited to be part of realizing Reata’s mission to improve the lives of people facing serious and life-threatening diseases.”
“I’m very pleased to welcome Dr. Edwards to Reata’s Board,” said Warren Huff, Reata’s Chairman, Chief Executive Officer and President. “He is a highly respected leader in our industry, with valuable experience across many organizations and therapeutic areas. Our Board and Company will benefit from his insights and counsel as Reata continues to make progress toward becoming a fully integrated, global, commercial enterprise.”
About Reata Pharmaceuticals, Inc.
Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two most advanced clinical candidates, bardoxolone methyl (“bardoxolone”) and omaveloxolone, target the important transcription factor Nrf2 that promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. Bardoxolone and omaveloxolone are investigational drugs, and their safety and efficacy have not been established by any agency.
